giles introduces AI agent to accelerate healthcare and life science research
AI tool connects researchers to verified medical and life sciences global databases, enabling accurate extraction and summarisation of academic papers, journals, and articles
Advertisement
giles AI, a company making advanced research tools accessible to all and simplifying how scientists work with data, has announced the commercial launch of giles, its AI specialised research agent designed to support healthcare, clinical, and medical research. By extracting, analysing, summarising, and referencing information from verified medical databases and private files, giles enables rapid literature review, accelerating research processes.
Using an LLM-agnostic approach, giles optimises research intelligence for scientific text comprehension, data accuracy validation, citation tracking, and domain-specific language understanding for medical, clinical, and academic settings. giles searches trusted sources of information, including private personal documents, to create easily digestible abstracts and comparisons of relevant data. In addition, it cites and verifies results, all completed within seconds. With an accuracy rate of up to 94% and available in over 40 languages, giles is applicable to all aspects of life science and healthcare research, including drug discovery and development, where the tool is enhancing workflows by providing access to real-time insights.
Following its initial development, refinement and subsequent commercialisation ofthe AI agent was supported through a strategic partnership with Regulatory Scientific and Health Solutions (R-S-S), a leader in health economics and drug development, to connect researchers with open access medical databases. With ongoing support from Google UK, giles AI now has a series of high-profile collaborations with pharma companies, directly connecting researchers to medical databases.
Rishi Wadhera, CEO of giles AI, said: “giles is transforming the way we approach medical research literature review. Instead of spending hours researching, analysing, and organising data, users can simply ask our innovative AI agent, making healthcare research effortless. We are excited to share giles with both academics and researchers from across sector as we advance in our mission to make advanced AI research tools available to all, and look forward to seeing the scientific breakthroughs our technology facilitates.”
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Faster and more reliable crystal structure prediction of organic molecules
Elevated hormone flags liver problems in mice with methylmalonic acidemia - Study findings can immediately be applied to human patients with the disease
Investigational monoclonal antibody to treat Ebola is safe in adults
NIH clinical trial of remdesivir to treat COVID-19 begins
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease
CORAT Therapeutics obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101 - COR-101 is a human antibody that blocks virus infection by binding to the spike protein
New muscle therapy gets fast-track boost - Berlin start-up could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process
SAS accelerates delivery of novel medicines using AI and analytics - Cooperation with AstraZeneca for more innovation in clinical research
Gentle protein purification at the touch of a button - i3 Membrane revolutionizes the separation of biological agents
Bio-based plastics for infusion bags - Frankfurt research team develops sustainable alternative to medical products made from crude oil in cooperation with bioplastics start-up BIOVOX
Recipharm secures major additional grant to develop AI-enabled manufacturing technologies - Development of an AI-enabled simulator and process control platform, to speed up process development, cut costs and improve manufacturing efficiency